PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Piotroski F-Score: 3 (As of Jun. 25, 2026) — 25% Below Median


CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
84 GF Score
Price MAD1,349.00
GF Value MAD1,327.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Piotroski F-Score?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 84 Piotroski F-Score is 3 as of Jun. 25, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates CAS:PRO with a GF Score™ of 84/100 and a GF Value™ of MAD1,327.72 (Fairly Valued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks worse than 78.39% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score or its related term are showing as below:

CAS:PRO' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 3

During the past 10 years, the highest Piotroski F-Score of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM was 7. The lowest was 2. And the median was 4.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM  (CAS:PRO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Piotroski F-Score Related Terms


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Piotroski F-Score Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 2.00 4.00 3.00

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 0.00 4.00 0.00 3.00

CAS:PRO vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score falls into.


CAS:PRO
84GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was MAD59.9 Mil.
Cash Flow from Operations was MAD0.0 Mil.
Revenue was MAD979.7 Mil.
Gross Profit was MAD424.7 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (1157.263 + 1219.928) / 2 = MAD1188.5955 Mil.
Total Assets at the begining of this year (Dec24) was MAD1,157.3 Mil.
Long-Term Debt & Capital Lease Obligation was MAD0.0 Mil.
Total Current Assets was MAD792.8 Mil.
Total Current Liabilities was MAD457.6 Mil.
Net Income was MAD55.2 Mil.

Revenue was MAD898.7 Mil.
Gross Profit was MAD389.9 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (984.532 + 1157.263) / 2 = MAD1070.8975 Mil.
Total Assets at the begining of last year (Dec23) was MAD984.5 Mil.
Long-Term Debt & Capital Lease Obligation was MAD0.0 Mil.
Total Current Assets was MAD760.8 Mil.
Total Current Liabilities was MAD379.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Income (TTM) was 59.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Cash Flow from Operations (TTM) was 0.0. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=59.915/1157.263
=0.05177302

ROA (Last Year)=Net Income/Total Assets (Dec23)
=55.16/984.532
=0.05602662

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's return on assets of this year was 0.05177302. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's return on assets of last year was 0.05602662. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Income (TTM) was 59.9. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Cash Flow from Operations (TTM) was 0.0. ==> 0.0 <= 59.9 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0/1188.5955
=0

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0/1070.8975
=0

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gearing of this year was 0. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=792.812/457.616
=1.73248313

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=760.776/379.713
=2.00355532

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ratio of this year was 1.73248313. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ratio of last year was 2.00355532. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's number of shares in issue this year was 0. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=424.749/979.734
=0.43353502

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=389.89/898.714
=0.43383101

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gross margin of this year was 0.43353502. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's gross margin of last year was 0.43383101. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=979.734/1157.263
=0.8465958

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=898.714/984.532
=0.91283371

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's asset turnover of this year was 0.8465958. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's asset turnover of last year was 0.91283371. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Piotroski F-Score of 3 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #769 out of 981 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 3 is 40% below this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #769 out of 981 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #769 out of 981 companies for Piotroski F-Score. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the lower half of its industry. The industry median Piotroski F-Score is 5.00. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 3 is 40% below this benchmark. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,327.72, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Drug Manufacturers industry median of 5.00. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Piotroski F-Score is 3 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,327.72. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: MAD1,327.72 vs. price of MAD1,349.00 (1.6% above fair value)
  • GF Score™: 84/100 with 6 warning signs
  • Industry Position: 40% below the Drug Manufacturers median (#769 of 981)

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score

Get the complete analysis for CAS:PRO

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,349.00
Price
MAD1,327.72
GF Value